Emergent BioSolutions (NYSE: EBS) will further develop a licensed drug against Ebola under a potential 10-year, $704 million contract from
The Department of Health and Human Services has outlined several focus areas of a $5 billion government initiative to fund
The Food and Drug Administration has awarded Booz Allen Hamilton (NYSE: BAH) and Octo Consulting Group spots on a potential
Four companies have won spots on a potential 10-year, $159 million contract to provide preclinical drug development support services for
The National Institute of Allergy and Infectious Diseases has awarded a division of SRI International a potential five-year, $100 million
